Clinical translation of human microRNA 21 as a potential biomarker for exposure to ionizing radiation

Halimi, Mohammad; Parsian, Hadi; Asghari, S. Mohsen; Sariri, Reyhaneh; Moslemi, Dariush; Yeganeh, Farshid; Zabihi, Ebrahim

doi:10.1016/j.trsl.2014.01.009

Cited by 29 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated evidence showed that circulating miRNAs could be potential biomarkers for early diagnosis and prognosis prediction in lung cancer [33, 34]. And miR-21 was verified as a biomarker for ionizing radiation in breast cancer [35]. However, there is no report about the role of plasma miRNAs in predicting radiosensitivity in NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

Liao

et al. 2016

Tumor Biol.

View full text Add to dashboard Cite

BackgroundRadioresistance of thoracic radiotherapy is a major bottleneck in the treatment of non-small cell lung cancer (NSCLC). Until now, there have been no effective biomarkers to predict the radiosensitivity.PurposesBased on miRNA profile screened from NSCLC cell lines with different radiosensitivity, this study was conducted to explore the correlation between plasma miRNAs and radiotherapy response in NSCLC patients, and to identify biomarkers of the radiosensitivity in NSCLC.MethodsDifferentially expressed genes were acquired from time-series gene expression profiles of radioresistant H1299 and radiosensitive H460 lung cancer cells (GSE20549). Potential miRNAs were screened from these differentially expressed genes by combining bioinformatics with GO analysis, pathway analysis, and miRNA prediction. A clinical observational study was performed to explore the correlation between candidate miRNAs and radiotherapy response. Stage IIIa–IV NSCLC patients who received two to four cycles of previous chemotherapy and underwent thoracic radiotherapy alone were included. Total RNA was purified from peripheral blood before radiotherapy, and plasma miRNAs were detected by real-time PCR (qRT-PCR). Then, tumor response, progression-free survival (PFS), and overall survival (OS) were acquired. Four miRNAs significantly different between effective and ineffective groups were further analyzed to obtain cutpoints from receiver operating characteristic (ROC) curves and the predictive value of radiosensitivity.ResultsCandidate miRNAs included 14 miRNAs screened from radioresistant genes and five from radiosensitive genes. From Jan., 2013 to Dec., 2014, 54 eligible patients were enrolled with a median follow-up of 15.3 months (range 4.6 to 31.4) by the deadline of Aug. 31, 2015. Totally, there were no case of complete response (CR), 15 of partial response (PR), 35 of stable disease (SD), and 4 of progressive disease (PD). Eight patients had no progression and 19 patients were still alive. The median PFS and OS were 6.6 months (range 2.3 to 29.3) and 15.3 months (range 4.6 to 31.4), respectively. Four miRNAs (hsa-miR-98-5p, hsa-miR-302e, hsa-miR-495-3p, and hsa-miR-613) demonstrated a higher expression in effective group (CR + PR, 15 cases) than in ineffective group (SD + PD, 39 cases). Based on each cutpoint, objective response rate (ORR) was higher in miR-high group than in miR-low group. No miRNA showed correlation with median PFS or OS.ConclusionBioinformatical analysis and clinical verification reveal the correlation between plasma miRNAs and radiosensitivity in NSCLC patients. Plasma miRNAs represent novel biomarkers to predict radiotherapy response clinically.Electronic supplementary materialThe online version of this article (doi:10.1007/s13277-016-5052-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

Liao

et al. 2016

Tumor Biol.

View full text Add to dashboard Cite

show abstract

“…Analysis of miR-21 expression levels in the serum of breast cancer patients at different treatment time points revealed significantly increased miR-21 levels after radiotherapy in those individuals who had received chemotherapy five weeks before radiation treatment (P , 0.001) (42). In addition, high plasma expression levels of miR-142-3p, -186-5p, -195-5p, -374b-5p and -574-3p after the second fraction of radiotherapy were shown to correlate with a poorer prognosis in patients with head and neck squamous cell carcinoma (43).…”

Section: Mirnas To Monitor Response To Radiotherapymentioning

confidence: 99%

MicroRNAs and Their Impact on Radiotherapy for Cancer

et al. 2016

View full text Add to dashboard Cite

“…[13][14][15][16] Radiation therapy leans on ROS (reactive oxygen species) toxicity and can damage cellular macromolecules, such as DNA (deoxyribonucleic acid), RNA (ribonucleic acid), microRNAs, proteins and membrane in tumor cells. [17][18][19] Antioxidants protect normal cells against radiation injury through various enzymatic systems, such as catalase, glutathione peroxidase and superoxide dismutase. In addition, normal cells would benefit from non-enzymatic systems (such as selenium, glutathione and tocopherol) to scavenge the free radicals.…”

Section: Introductionmentioning

confidence: 99%